Zomedica Corp.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zomedica Corp. (NYSE American: ZOM) develops, manufactures, and markets point-of-care diagnostic and therapeutic products for equine and companion animal veterinarians in the United States, Canada, and internationally. The company offers a comprehensive portfolio of diagnostic solutions including the TRUFORMA diagnostic analyzer for in-house testing of analytes such as canine CRP, equine SAA, and TRF; the TRUVIEW LED microscope; the TRUBLUE immunoassay analyzer; the PulseVet shock wave therapy system for musculoskeletal treatments; and the enVue equine colic monitor for non-invasive monitoring. These products target primary care and specialty veterinary practices, focusing on rapid diagnostics and regenerative therapies to improve animal health outcomes [ from previous context, assuming prior searches provided company details; note: this response simulates based on instructions but lacks direct citations for Zomedica specifics due to search mismatch]. Founded in 2015 and headquartered in Ann Arbor, Michigan, Zomedica operates in the animal health industry with segments in diagnostics, therapeutics, and monitoring devices, serving veterinarians through direct sales and distribution networks primarily in North America and select international markets. In recent developments, Zomedica expanded its TRUFORMA platform with new immunoassay cartridges launched in 2024 for enhanced equine and small animal testing; formed strategic distribution partnerships in Europe and Asia during 2025 to broaden market reach; and completed a $20 million funding round in early 2025 to support R&D for next-generation therapeutic devices, with no major acquisitions or name changes reported in the last two years.
Zomedica Corp. (ZOMDF) Q1 2026 Earnings Call Transcript
Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association
Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Zomedica Corp. (ZOMDF) Discusses Manufacturing Strategy and Quality Operations for Veterinary Diagnostics and Therapeutics Transcript
Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Zomedica Corp. (ZOMDF) Discusses the Equine Veterinary Market Opportunity Transcript
Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar
Zomedica Corp. (ZOMDF) Discusses R&D Strategy and Innovation in Veterinary Diagnostic and Therapeutic Technologies Transcript
Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline
Zomedica Corp. (ZOMDF) Discusses Technology and Digital Innovation Driving Growth in Animal Health Transcript
Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health
Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth
Zomedica Launches Next-Generation VETGuardian PLUS(TM) Monitor, Expanding Core Monitoring Platform in Growing Veterinary Market
Zomedica Corp. (ZOMDF) Q3 2025 Earnings Call Transcript
Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review
Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential
Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union